Recent fate-mapping studies concluded that EMT is not required for metastasis of carcinomas. Here we challenge this conclusion by showing that these studies failed to account for possible crosstalk between EMT and non-EMT cells that promotes dissemination of non-EMT cells. In breast cancer models, EMT cells induce increased metastasis of weakly metastatic, non-EMT tumour cells in a paracrine manner, in part by non-cell autonomous activation of the GLI transcription factor. Treatment with GANT61, a GLI1/2 inhibitor, but not with IPI 926, a Smoothened inhibitor, blocks this effect and inhibits growth in PDX models. In human breast tumours, the EMT-transcription factors strongly correlate with activated Hedgehog/GLI signalling but not with the Hh ligands. Our findings indicate that EMT contributes to metastasis via non-cell autonomous effects that activate the Hh pathway. Although all Hh inhibitors may act against tumours with canonical Hh/GLI signalling, only GLI inhibitors would act against non-canonical EMT-induced GLI activation.
Tumor heterogeneity is a major obstacle to the development of effective therapies and is thus an important focus of cancer research. Genetic and epigenetic alterations, as well as altered tumor microenvironments, result in tumors made up of diverse subclones with different genetic and phenotypic characteristics. Intratumor heterogeneity enables competition, but also supports clonal cooperation via cell-cell contact or secretion of factors, resulting in enhanced tumor progression. Here, we summarize recent findings related to interclonal interactions within a tumor and the therapeutic implications of such interactions, with an emphasis on how different subclones collaborate with each other to promote proliferation, metastasis and therapy-resistance. Furthermore, we propose that disruption of clonal cooperation by targeting key factors (such as Wnt and Hedgehog, amongst others) can be an alternative approach to improving clinical outcomes.
Epithelial-to-mesenchymal transition (EMT) is a dynamic process that
relies on cellular plasticity. Recently, the process of an oncogenic EMT,
followed by a reverse mesenchymal-to-epithelial transition (MET), has been
implicated as critical in the metastatic colonization of carcinomas. Unlike
governance of epithelial programming, regulation of mesenchymal programming is
not well understood in EMT. Here, we describe and characterize the first
microRNA that enhances exclusively mesenchymal programming. We demonstrate that
microRNA-424 is upregulated early during a TWIST1 or SNAI1-induced EMT, and that
it causes cells to express mesenchymal genes without affecting epithelial genes,
resulting in a mixed/intermediate EMT. Furthermore, microRNA-424 increases
motility, decreases adhesion and induces a growth arrest, changes associated
with a complete EMT, that can be reversed when microRNA-424 expression is
lowered, concomitant with an MET-like process. Breast cancer patient
microRNA-424 levels positively associate with TWIST1/2 and EMT-like gene
signatures, and miR-424 is increased in primary tumors versus matched normal
breast. However, microRNA-424 is downregulated in patient metastases versus
matched primary tumors. Correspondingly, microRNA-424 decreases tumor initiation
and is post-transcriptionally downregulated in macrometastases in mice,
suggesting the need for biphasic expression of miR-424 to transit the EMT-MET
axis. Next-generation RNA sequencing revealed microRNA-424 regulates numerous
EMT and cancer stemness-associated genes, including TGFBR3, whose downregulation
promotes mesenchymal phenotypes, but not tumor-initiating phenotypes. Instead,
we demonstrate that increased MAPK/ERK signaling is critical for
miR-424-mediated decreases in tumor-initiating phenotypes. These findings
suggest microRNA-424 plays distinct roles in tumor progression, potentially
facilitating earlier, but repressing later, stages of metastasis by regulating
an EMT-MET axis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.